Turning promising university research into real-world products requires strong partnerships between researchers, startups, investors, and universities. One important part of that process is establishing a license agreement that gives a new company the rights it needs to commercialize university technology. While these agreements must balance the interests of all parties and often require careful negotiation, many early-stage transactions share common elements.
Innovation UBC's Express License was created to simplify those discussions by offering a standardized framework for spin-off companies. Our latest update builds on years of experience and stakeholder feedback, making the process even more efficient, transparent, and founder-friendly.
What is UBC’s Express License Agreement (ELA)?
The ELA is a ready-to-sign, standardized licensing contract that lets a researcher at the University of British Columbia, who wants to commercialize the technology they invented at UBC, form a spin-off. Instead of negotiating a custom licensing agreement, the spin-off adopts a pre-built agreement with fixed, transparent terms: exclusive, worldwide rights to use and sublicense the UBC technology, while UBC maintains the right to use it for research and teaching. Think of it as a licensing template, one that has already been vetted by investors, law firms, and entrepreneurs, that a founder can pick up and run with.
Why is the ELA important?
UBC spin-offs turn university discoveries into products and services for public benefit, and the challenge has always been getting the deal done without burning time and money. The ELA solves that for everyone at the table:
- For researchers and founders, it removes the single biggest early friction point: no months of legal wrangling, no large up-front bills, predictable terms from day one.
- For UBC, it ensures every spin-off receives the same fair, benchmarked deal, protects the university's academic mission, and keeps UBC invested in each venture's success.
- For industry and investors, it offers speed and certainty, with standardized terms and known liabilities that mean fewer surprises in due diligence.
UBC's Express License Agreement has been in place since April 2025, and in June 2026 it got a significant refresh. Here are the key takeaways, covering how the ELA works overall and what changed in the latest version.
Takeaway #1: Speed is a benefit, reducing time and money
Non-negotiable means fast, and speed is the advantage. Instead of spending six months and thousands of dollars on legal counsel to draft a custom contract, founders can adopt a vetted, industry-benchmarked agreement immediately. That standardization eliminates transaction costs, gives instant clarity on commercialization expectations, and lets researchers stay focused on their science and customers rather than legal minutiae.
Takeaway #2: The "future-proof" clause (access to improvements)
Your license keeps up with the lab, and ownership works in your favor on both sides. The ELA gives the spin-off access to future improvements and enhancements made by UBC, folded into the existing license with no separate fee or renegotiation. This typically covers improvements made within five years of the start date by the original investigators. Access to this "long tail" of university research is not the North American norm and is an exciting component of UBC’s ELA. Just as important, anything the spin-off develops independently after signing belongs to the company outright.
Takeaway #3: UBC owns the patents, you help drive them
UBC holds and protects all patents; the spin-off funds them and can take the wheel later. UBC covers the first C$20,000 of total patent expenses, and after the license is signed, the spin-off is responsible for anything above that. Then, once the company is on a stable financial footing, it can take over patent management with UBC's approval, choosing its own counsel and deciding which countries to file and maintain in. That control extends to enforcement: if someone infringes, the company holds the first right to sue.
Takeaway #4: Equity and the "anti-dilution" shield
UBC and the non-founder inventors receive a total 5% founding equity stake. Additionally, an anti-dilution shield maintains that 5% until the company raises $2 million in equity financing or achieves $2 million in cumulative net sales and sublicensing revenue. The financial obligations are transparent and built to preserve early-stage cash flow:
- Royalties on net sales: 2% in countries with patent coverage, 1% in non-patented jurisdictions.
- Sublicensing revenue: a tiered share based on the technology's development stage (see Takeaway #6).
- Annual license fees: starting at $5,000 (years 2 and 3), rising to $10,000 (years 4 and 5), and $20,000 (year 6 and beyond).
- Royalty-stacking relief: if you must license a third party's patent to ship your product, UBC will cut its own royalty by up to half.
- Non-cash revenue flexibility: where sublicensing revenue arrives as equity or another non-cash form, the company now determines how to pay UBC's share.
Beyond the financial terms, all shareholders (founders, UBC, and any non-founder inventors) sign a shareholders' agreement setting out everyone's rights as owners. UBC keeps this practical, accepting standard formats like the CVCA model agreements with only minor changes.
Takeaway #5: Radical transparency in sublicensing
Partner on merit, not balance sheet size. The former $100M market-cap gate for sublicensees has been replaced with a practical "financial and technical capability" test, letting companies partner with the best-fit global players. Sub-sublicensing is also now explicitly permitted, giving partners the flexibility to build their own networks on the licensed technology. UBC uses a tiered revenue-sharing model, with rates tied to milestones typically tailored to the technology type (for example, clinical trial phases or regulatory approvals):
| Stage of development of most advanced product | UBC share of sublicensing revenue |
| Early stage (prior to defined milestone) | 20% |
| Mid-stage development | 15% |
| Late stage (near commercialization) | 10% |
Affordable Access: For life-science products, the ELA also includes Global Access provisions, designed to help medicines from UBC research reach low- and middle-income countries and underserved populations in Canada, not just the highest-paying markets.
Takeaway #6: The license is built to survive an exit or challenging times
The IP travels cleanly through an acquisition. The license can be assigned in a sale or merger, provided UBC gets notice; the buyer is capable and reputable and agrees to the same terms, and a $20,000 assignment fee is paid. Downstream partners are protected too: if the main license is ever terminated, sublicensees in good standing can step into the company's place by agreeing to UBC's terms directly, so a partner's rights do not evaporate because of a problem one level up.
UBC’s right to terminate upon company insolvency has also been narrowed and made more flexible, giving companies more room to restructure or work through financial difficulty without automatically losing their license.
Takeaway #7: The fine print
Real upside comes with real obligations. The ELA expects progress: the company must be adequately capitalized within 24 months, appoint its first independent director within 12 months and a second within 36, and use commercially reasonable efforts to commercialize.
On risk, UBC caps its own liability at $10,000, makes no warranty that the technology is free to operate or free of third-party infringement, and asks the company to indemnify it against claims arising from the venture's use of the technology. None of this is unusual for university licensing, and investors will see it in diligence regardless, so the honest takeaway for founders is simple: do your own freedom-to-operate and technical due diligence early, and put the time the ELA frees up toward exactly that.
Conclusion: The future of UBC innovation
The ELA reflects a simple bet: the fastest way to get research out of the lab and into the world is to remove friction, not add to it. By trading drawn-out negotiation for transparent, benchmarked terms, and tuning those terms to how startups actually raise money and grow, UBC has turned its licensing process from a bottleneck into a launchpad.
